Boehringer Ingelheim’s Post

𝐋𝐢𝐥𝐥𝐲 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥𝐬 𝐨𝐟 𝐎𝐧𝐜𝐞-𝐖𝐞𝐞𝐤𝐥𝐲 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐄𝐟𝐬𝐢𝐭𝐨𝐫𝐚 Lilly Eli Lilly and Company has revealed positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once-weekly insulin efsitora in adults with type 2 diabetes. These trials demonstrated non-inferior A1C reduction compared to daily basal insulins, indicating the potential to simplify diabetes management. Efsitora, delivered through a simple fixed-dose regimen, could make insulin therapy more manageable and reduce the burden on patients. QWINT-1 and QWINT-3 trials showed efsitora achieved significant A1C reduction in insulin-naïve patients and those switching from daily basal insulin injections. The safety profile of efsitora was similar to that of daily basal insulins, with reduced rates of severe hypoglycemia. Detailed results will be shared at future congresses. #DiabetesCare #Type2Diabetes #InsulinInnovation #PharmaNews #ClinicalTrials #DiabetesManagement #Efsitora #Lilly

Today’s FDA-approved #obesity medications are primed to become tomorrow’s novel treatments across multidimensional states of disease – from #diabetes to heart failure. In our latest article, nephrologist and Biorasi SAB member, Jamie P. Dwyer, MD, discusses the concept of #diabesitology and the potential of drugs on the #GLP1 axis >> https://bit.ly/3V6CKDm

📌 Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. 📌 This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/ EZE as single-pill combination in the setting of real clinical practice in Italy. 📌 In a dyslipidemic population previously treated with ROS/EZE as free pill combination, the proportion of adherent patients significantly increased (from 51.8% to 75.1%) after switching to single-pill combination. 📌 These findings confirm that simplifying lipid- lowering therapy through single-pill combination of ROS/EZE represents a valid strategy to improve medication adherence, which is essential for increasing the likelihood of reaching the recommended LDL-C targets to improve cardiovascular outcomes, with the ultimate goal of alleviating the clinical and economic burden related to ASCVD. #Adherence #Rosuvastatin #Ezetimibe #SinglePillCombination #RealWorldEvidence Follow-us CliCon S.r.l. Società Benefit

There are tens of thousands of patients in the US that have been using acid-suppression therapy for years at a time. Could this be causing the dramatic increase in migraines? --- Throughout #pharmacy school, I wondered why so many patients were on acid-suppression therapy as a chronic medication. These therapies (listed below) are only indicated for short term use, such as a few weeks at a time. -Proton pump inhibitors (PPIs) -H2 receptor antagonists (H2RAs) -Antacids --- When patients take these therapies chronically (whether from the patient's desire or unaware clinicians), they can cause issues with mineral absorption. A recent study (in the comments) also observed patients had higher odds of severe #headaches and #migraines from chronic use of these medications. -PPIs (70% higher) -H2RAs (40% higher) -Antacids (30% higher) --- This was an observational study, so we can't say for sure causality. However, it does have the same findings as other studies on PPIs. This may be one of the causes for the dramatic increase in migraines and the utilization of migraine medications. Does any #pharmacist out there recommend chronic acid suppression therapy?

A network meta-analysis and meta-regression of intraclass comparison of inhaled corticosteroids for the risk of pneumonia in chronic obstructive pulmonary airway disorder. Class differences in pneumonia risk were observed in terms of pooled effect estimates but it is unlikely that any clinically relevant differences exist. Risk–benefit analysis supports inhaled corticosteroid use in moderate-severe COPD. Derek Stewart European Society of Clinical Pharmacy (ESCP) Yolande Hanssens Vibhu Paudyal Shusen Sun Filipa Alves da Costa Matej Štuhec PharmD PhD Univ.-Prof. Dr. Anita Weidmann Kannan Sridharan #pharmacy #pharmacists #pharmacylife #clinicalpharmacy #pharmaceuticalcare #pharmacycollege #pharmacystudents #pharmacytechnicians https://lnkd.in/dbMk5YAh

🌠Acute liver failure is a rapid onset of impaired hepatic function, occurring within days or weeks, and typically affects individuals without preexisting liver conditions. The leading causes are the hepatitis virus and pharmaceuticals, including acetaminophen. Acute liver failure is less prevalent in comparison to the gradual progression of chronic liver failure. 🌠Acute liver failure, alternatively referred to as fulminant hepatic failure, has the potential to induce severe complications such as cerebral hypertension and haemorrhage. A medical emergency of this nature necessitates hospitalisation. 🌠Treatment may occasionally be able to reverse acute liver failure, contingent upon the underlying cause. But in numerous instances, a liver transplant might be the sole curative option. Source: Mayo Clinic #acuteliverfailure #impairedhepaticfunction #disabilityaustralia #disabilityrights #disabilitylife #invisibledisability #disabilitysupport #disabilityisnotinability #disabilityisdiversity #disabilitypride #disabilityinclusion #abilitynotdisability #invisibledisability #disabilitysolidarity #disabilityconfident #disabilityisbeautiful #disabilitygamechanger #disabilityawareness

The FDA is adding a Boxed Warning to the Prolia (denosumab) prescribing information concerning the significant risk of developing severe hypocalcemia in patients with advanced chronic kidney disease (CKD), particularly patients on dialysis. Severe hypocalcemia appears to be more common in patients with CKD who also have mineral and bone disorder. In patients with advanced CKD taking Prolia, severe hypocalcemia resulted in serious harm, including hospitalization, life-threatening events, and death. Severe hypocalcemia can be asymptomatic or may present as confusion; seizures; arrhythmias; fainting; face twitching; uncontrolled muscle spasms; or weakness, tingling, or numbness in parts of the body. In addition to the Boxed Warning, the prescribing information will be updated to include information on how to reduce the risk of hypocalcemia, including appropriate patient selection for Prolia treatment, monitoring of calcium levels, and other strategies. The updated safety information will also be incorporated into the Medication Guide and the Prolia Risk Evaluation and Mitigation Strategy (REMS). Further information can be found at https://lnkd.in/dp_umpdP Brand Names: US Prolia; Xgeva Brand Names: Canada Prolia; Xgeva Therapeutic Category Bone-Modifying Agent; Monoclonal Antibodies Dosage guidance: Clinical considerations: Administer calcium and vitamin D as necessary to prevent or treat hypocalcemia. #fdaapproved #medicines #clinicalpharmacy #alert #safety #healthcare

There is more and more evidence suggesting that warfarin isn´t going away because it is more effective or safer in high thrombosis risk patients (mechanical heart valves, rheumatic heart disease, lupus anticoagulant, frail elderly with atrial fibrillation). But what if warfarin can be made even more effective by replacing the ancient monitoring method, the PT-INR with the Fiix test (Fiix normalized ratio)? On April 5th I will orally present a paper (GROAC study = Greater Reykjavik Oral Anticoagulant Study) at the Thrombosis and Haemostasis Summit of North America; THSNA) in Chicago demonstrating based on real-world propensity score weighted data that Fiix-warfarin (ie Fiix-NR monitored warfarin) leads to significantly better outcome in non-valvular atrial fibrillation patients than do DOAC drugs and conventionally managed warfarin the main improvement being a reduced acute myocardial infarction rate in AF patients! Bleeding rate is similar. These results confirm a subgroup analysis of the Fiix trial which suggested improved outcome with Fiix warfarin in AF patients. But it adds that the outcome is also better than that observed with the more convenient DOAC drugs that are currently recommended as first-line agents in non-valvular AF. We have now been fighting for almost 15 years now to prove that factor VII should be ignored during warfarin monitoring . This is the third clinical study supporting the concept but the results have been largely brushed aside sofar by the professional community. Exciting? Could this change practice? Should the laboratories start providing Fiix-NR to clinicians and dosing staff? #thrombosis #atrialfibrillation #medicine  #healthcare  #clinicaltrials  #clinicalresearch #nationalbloodclotalliance

BOXED WARNING FOR DENOSUMAB Based on a completed U.S. Food and Drug Administration (FDA) review of available information, FDA have concluded that the osteoporosis medicine Prolia (denosumab) increases the risk of severe hypocalcemia, very low blood calcium levels, in patients with advanced chronic kidney disease (CKD), particularly patients on dialysis. Severe hypocalcemia appears to be more common in patients with CKD who also have a condition known as mineral and bone disorder (CKD-MBD). In patients with advanced CKD taking Prolia, severe hypocalcemia resulted in serious harm, including hospitalization, life-threatening events, and death. As a result, FDA is revising the Prolia prescribing information to include a new Boxed Warning, FDA’s most prominent warning, communicating this increased risk. Severe hypocalcemia can be asymptomatic or may present with symptoms that include confusion; seizures; irregular heart rhythm; fainting; face twitching; uncontrolled muscle spasms; or weakness, tingling, or numbness in parts of the body.

The STEP-HFpEF DM Trial builds on the STEP-HFpEF Trial. This study examined whether #semaglutide 2.4 mg weekly, aka #wegovy, decreased symptoms in people with #heartfailure with preserved ejection fraction, obesity, and type 2 #diabetes. Some highlights are below. - The semaglutide group improved symptoms more than the placebo group - The semaglutide group lost more weight than the placebo group (9.8% vs 3.1%) although not as much weight as those without diabetes in the STEP-HFpEF Trial - The semaglutide group improved 6-minute walk distance over the placebo group - The semaglutide group had better outcomes in most secondary and exploratory endpoints over the placebo group, such as #inflammation and heart failure events although the study wasn't designed for those primarily - An interesting finding was there was no more dropout in the semaglutide group than the placebo group (16.1% vs 15%) - Semaglutide was better than placebo even in those taking SGLT2 inhibitors for the primary endpoints I believe in the future we are going to see GLP-1 drugs used as a treatment for HFpEF, a notoriously difficult to treat type of heart failure with few specific treatments. It's an exciting time for the intersection between #obesitymedicine and #cardiovascular medicine! Link to both studies in comments.